NCT04080453View on ClinicalTrials.gov

Pro-inflammatory Role of Blood Platelets in Critically Ill Patients With Septic Shock.

CompletedOBSERVATIONAL
Enrollment

202

Participants

Timeline

Start Date

November 9, 2020

Primary Completion Date

February 9, 2024

Study Completion Date

April 25, 2024

Conditions
Septic Shock
Interventions
OTHER

Septic shock

Plasma concentration in CD154, beta thromboglobulin, platelet factor 4, platelet microparticles, soluble CD62, RANTES, GRO-alpha, HMGB-1, monocyte Dnases signal, circulating free DNA and DNase1 and DNase1L3 activities will be studied and compared at inclusion (Day 0), Day 1 and Day 5.

OTHER

Systemic Inflammatory Response Syndrome

Plasma concentration in CD154, beta thromboglobulin, platelet factor 4, platelet microparticles, soluble CD62, RANTES, GRO-alpha, HMGB-1, monocyte Dnases signal, circulating free DNA and DNase1 and DNase1L3 activities will be studied and compared at inclusion (Day 0), Day 1 and Day 5.

Trial Locations (1)

33604

Hôpital Haut Lévêque, Pessac

All Listed Sponsors
collaborator

MSD France

INDUSTRY

lead

University Hospital, Bordeaux

OTHER

NCT04080453 - Pro-inflammatory Role of Blood Platelets in Critically Ill Patients With Septic Shock. | Biotech Hunter | Biotech Hunter